JAZZ PHARMACEUT. DL-,0001
JAZZ PHARMACEUT. DL-,0001/ IE00B4Q5ZN47 /
J7Z
17/05/2024 8:08:13
|
Diferencia
+0.90
|
Volumen |
Bid20:59:37 |
Ask20:59:37 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
101.10EUR
|
+0.90%
|
0 Volumen de negocios: 0.00 |
99.56Volumen de oferta: 200 |
100.00Tamaño/ Volumen/ Formato de Ask: 200 |
6.32 mil millonesEUR |
- |
- |
Descripción de negocio
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.
Consejo de gestión & Consejo de supervisión
CEO |
Bruce C. Cozadd |
Consejo de gestión |
Pater Gray, Jeninfer Cook, Patrcik G. Enright, Heather Ann McSharry, Seamus Mulligan |
Consejo de supervisión |
- |